Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.15252/embr.202152447 http://scihub22266oqcxt.onion/10.15252/embr.202152447 34142428!8339669!34142428     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       EMBO+Rep 2021 ; 22 (8): e52447 Nephropedia Template TP {{tp|p=34142428|t=2021. Inclusion of cGAMP within virus-like particle vaccines enhances their immunogenicity |pdf=|usr=}}{{34142428}} gab.com Text Inclusion of cGAMP within virus-like particle vaccines enhances their immunogenicity JO: EMBO Rep http://www.kidney.de/pget.php?&tw=1&pmid=34142428 #FOAvip Cyclic GMP-AMP (cGAMP) is an immunostimulatory molecule produced by cGAS that activates STING. cGAMP is an adjuvant when administered alongside antigens. cGAMP is also incorporated into enveloped virus particles during budding. Here, we investigate whether inclusion of cGAMP within viral vaccine vectors enhances their immunogenicity. We immunise mice with virus-like particles (VLPs) containing HIV-1 Gag and the vesicular stomatitis virus envelope glycoprotein G (VSV-G). cGAMP loading of VLPs augments CD4 and CD8 T-cell responses. It also increases VLP- and VSV-G-specific antibody titres in a STING-dependent manner and enhances virus neutralisation, accompanied by increased numbers of T follicular helper cells. Vaccination with cGAMP-loaded VLPs containing haemagglutinin induces high titres of influenza A virus neutralising antibodies and confers protection upon virus challenge. This requires cGAMP inclusion within VLPs and is achieved at markedly reduced cGAMP doses. Similarly, cGAMP loading of VLPs containing the SARS-CoV-2 Spike protein enhances Spike-specific antibody titres. cGAMP-loaded VLPs are thus an attractive platform for vaccination. Twit Text FOAVip Inclusion of cGAMP within virus-like particle vaccines enhances their immunogenicity ????EMBO Rep http://www.kidney.de/pget.php?&tw=1&pmid=34142428 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34142428 #FOAvip English Wikipedia <ref>{{Cite pmid|34142428}}</ref> Inclusion of cGAMP within virus-like particle vaccines enhances their immunogenicity #MMPMID34142428 Chauveau L; Bridgeman A; Tan TK; Beveridge R; Frost JN; Rijal P; Pedroza-Pacheco I; Partridge T; Gilbert-Jaramillo J; Knight ML; Liu X; Russell RA; Borrow P; Drakesmith H; Townsend AR; Rehwinkel J EMBO Rep 2021[Aug]; 22 (8): e52447 PMID34142428show ga Cyclic GMP-AMP (cGAMP) is an immunostimulatory molecule produced by cGAS that activates STING. cGAMP is an adjuvant when administered alongside antigens. cGAMP is also incorporated into enveloped virus particles during budding. Here, we investigate whether inclusion of cGAMP within viral vaccine vectors enhances their immunogenicity. We immunise mice with virus-like particles (VLPs) containing HIV-1 Gag and the vesicular stomatitis virus envelope glycoprotein G (VSV-G). cGAMP loading of VLPs augments CD4 and CD8 T-cell responses. It also increases VLP- and VSV-G-specific antibody titres in a STING-dependent manner and enhances virus neutralisation, accompanied by increased numbers of T follicular helper cells. Vaccination with cGAMP-loaded VLPs containing haemagglutinin induces high titres of influenza A virus neutralising antibodies and confers protection upon virus challenge. This requires cGAMP inclusion within VLPs and is achieved at markedly reduced cGAMP doses. Similarly, cGAMP loading of VLPs containing the SARS-CoV-2 Spike protein enhances Spike-specific antibody titres. cGAMP-loaded VLPs are thus an attractive platform for vaccination. |*COVID-19[MESH] |*Influenza Vaccines[MESH] |*Vaccines, Virus-Like Particle/genetics[MESH] |Animals[MESH] |Humans[MESH] |Mice[MESH] |Nucleotides, Cyclic[MESH] |SARS-CoV-2[MESH]Inclusion of cGAMP within virus-like particle vaccines enhances their (epmc).pdf DeepDyve Pubget Overpricing